
Delivers a unique BPO formulation to the pores

• Proprietary formulation in CLENZIderm M.D.™ helps bioavailable BPO enter the follicle, where *P. acnes* is focused^{1,2,5,*,†}

CLENZIderm M.D.[™] BP0 molecule penetrates the hair follicle



CLENZIderm M.D.[™] clears acne at the source

- Complete system quickly reduces acne in as early as 1 week^{3,‡} and helps prevent future breakouts^{1,*}
- 5% BPO treats acne-causing *P. acnes* bacteria within the follicles^{1,2,6,7,*,†}
- The majority of patients were satisfied with the improvement in their acne and the system efficacy^{3,‡}
- *Study results for a split-face evaluation of the intrafollicular bactericidal activity of a novel BPO formulation...N=24. Obagi Cosmeceuticals LLC. Data on file.

^tStudy results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilized 5% BPO formulation...N=139. Obagi Cosmeceuticals LLC. Data on file.

[‡]Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZIderm M.D.[™] System; N=22.



To purchase the CLENZIderm M.D.[™] System, talk to your physician today. Find them via www.obagi.uk.com

References: 1. Erianne J, Prince DL, Ramirez J, Wilson D, Zeichner J. The pharmacologic science of a novel benzoyl peroxide formulation and the implications for clinical effects. Poster presented at: Clinical Dermatology Conference; October 6-9, 2006; Las Vegas, NV, Z. Thiboutto D, Eichenfield LF, Shalitta A, et al. Comparison of a 3-step acne system containing solubilized benzoyl peroxide...Obagi Cosmeceuticals LLC. Data on file. 3. Swinyer L, Investigator. A single-center, open-label study to evaluate the tolerability and efficacy of the optimized CLENZ(derm M.D. System for the treatment of mild to moderate facial acne vulgaris. Protocol CLZ-003. 12-week final analysis, January 2012. Obagi Cosmeceuticals LLC. Data on file. 4. Ramirez J, Faryniarz J. Benzoyl peroxide: notes on molecular dimensions. Technical report and microscopic observation. JR Chemical, Inc., Milford, CT, April 18, 2005. Obagi Cosmeceuticals LLC. Data on file. 5. Spellman MC, Ramirez J. A comparison of patterns of deposition of two formulations of benzoyl peroxide on the skin and in the follicular ostia as visualized by scanning electronic microscopy [poster]. Obagi Cosmeceuticals LLC. Data on file. 6. Cotteril JJA Benzoyl peroxide. Acta Derm Venereol *Suppl* (Stockh). 1980;suppl 89:57-63. 7. Russell JJ. Topical therapy for acne. *Am Fam Physician*. 2000;f1(2):357-365. 8. NIH. Salicylic acid topical. MedlinePlus website. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607072.html. Accessed January 15, 2015.

All products/brand names, whether designated by notice or not (B/T^{M}) , are trademarks of Obagi Cosmeceuticals LLC. Distributed by Obagi Cosmeceuticals LLC.

©2018 Obagi Cosmeceuticals LLC. All rights reserved. 9/18 CLZ.0025.USA.18.r1



CLENZIDERM M.D.™ SYSTEM



Clear your acne from the inside out



*Study results for a split-face evaluation of the intrafollicular bactericidal activity of a novel BPO formulation...N=24. Obagi Cosmeceuticals LLC. Data on file.

⁺Study results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilised 5% BPO formulation...N=139. Obagi Cosmeceuticals LLC. Data on file.

For more information, visit www.obagi.uk.com

CLENZIderm M.D.™ gets to the source to treat mild to moderate acne

- Penetrates to reach bacteria in the pores^{1,2,*,†}
- Reduces breakouts in as little as 1 week with continued results through 12 weeks^{3,‡}
- Helps prevent future breakouts^{1,*}

A highly effective, yet tolerable svstem^{3,‡}



*Study results for a split-face evaluation of the intrafollicular bactericidal activity of a novel BPO formulation...N=24. Obagi Cosmeceuticals LLC. Data on file.

[†]Study results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilised 5% BPO formulation... N=139. Obagi Cosmeceuticals LLC. Data on file

[‡]Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZIderm M.D.[™]System; N=22.

See results as early as week 1^{3,‡}



At week 12^{3,‡}:

- 81% of patients were satisfied or very satisfied with their acne improvement
- 87% reported that the system was effective or very effective




Baseline[§]

Week 12§ §Photos have not been retouched. Results may vary.

[‡]Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZIderm M.D.[™] System; N=22.

Early and continuous acne breakout reduction^{3,*,‡}



- Reduces acne breakouts in as little as 1 week^{3,‡}
- Continues to reduce acne lesions through 12 weeks of use^{3,‡}
- Proven effective in treating mild to moderate acne^{3,‡}

Two key ingredients make CLENZIderm M.D.[™] effective

5% BPO gets delivered to the follicles to reach the source of acne, *P. acnes* Salicylic acid promotes cell turnover

to open clogged pores and helps minimise swelling and redness^{7,8}

*Do not use if you have very sensitive skin or are sensitive to benzoyl peroxide. For external use only.

[†]Study results for a 10-week evaluation of twice-daily use of a 3-step acne system containing a novel solubilized 5% BPO formulation...N=139. Obagi Cosmeceuticals LLC. Data on file.

[‡]Study results for a 12-week evaluation of the efficacy and tolerability of daily application of the CLENZIderm M.D.[™]System; N=22.